Lexaria Bioscience Reaches Full Enrollment in Oral Semaglutide Study

• Lexaria Bioscience reported full enrollment in its GLP-1-H26-7 human pilot study on October 21, 2026, with dosing on schedule.
• The five-week trial compares two oral DehydraTECH-semaglutide formulations with Novo's Wegovy tablets, assessing safety, tolerability and drug absorption.
• The final study group began dosing in early October and is expected to finish in mid-November.
• Results will follow completion of dosing and laboratory analyses; a progress update is planned once dosing ends.
• Existing corporate resources fully fund the study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610210925ACCESSWRNAPR_____1239158) on October 21, 2026, and is solely responsible for the information contained therein.